Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 38, 2003 - Issue 8
Submit an article Journal homepage
110
Views
52
CrossRef citations to date
0
Altmetric
Research Article

Hepatitis C in the General Adult Population of Oslo: Prevalence and Clinical Spectrum

Dalgard O. Medical Dept. Aker University Hospital Oslo Norway
,
Jeansson S. Microbiological Dept. Ullevål University Hospital Oslo Norway
,
Skaug K. Norwegian Institute of Public Health Ullevål University Hospital Oslo Norway
,
Raknerud N. Dept. of Pathology Aker University Hospital Oslo Norway
&
Bell H. Medical Dept. Aker University Hospital Oslo Norway
Pages 864-870 | Published online: 08 Jul 2009

  • World Health Organization. Hepatitis C: global prevalence. Weekly epidemiological record. Geneva, Switzerland; 1997;46: 341-4.
  • Garcia-Fulgueiras A, Tormo MJ, Rodriguez T, Perez-Flores D, Chirlaque D, Navarro C. Prevalence of hepatitis B and C markers in the south-east of Spain: an unlinked community-based serosurvey of 2,203 adults. Scand J Infect Dis 199628:17-20.
  • Bellentani S, Pozzato G, Saccoccio G, Crovatto M, Croce LS, Mazzoran L, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999;44:874-80.
  • Dubois F, Desenclos JC, Mariette N, Goudeau A. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology 1997;25:1490-6.
  • Palitzsch KD, Hottentrager B, Schlottmann K, Frick E, Holstege A, Scholmerich J, et al. Prevalence of antibodies against hepatitis C virus in the adult German population. Eur J Gastroenterol Hepatol 1999;11:1215-20.
  • Hoffmann G, Berglund G, Elmstahl S, Eriksson S, Verbaan H, Widell A, et al. Prevalence and clinical spectrum of chronic viral hepatitis in a middle-aged Swedish general urban population. Scand J Gastroenterol 2000;35:861-5.
  • Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992;327:1906-11.
  • Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-33.
  • Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype lb) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000;32: 91-6.
  • Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349:825-32.
  • Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. JAIDS 1998; I8 Suppl 1:S11-9.
  • Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
  • Agresti A, Caffo B. Simple and effective confidence intervals for proportions and differences of proportions result from adding two successes and two failures. Am Stat 2000;54:280-4.
  • Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62.
  • Eskild A, Samdal HH, Skaug K, Jeansson S, Stray-Pedersen B, Jenum PA. Prevalence of antibodies against hepatitis C virus among pregnant women and the risk of fetal death. Tiskr Nor Laegeforen 2000;120:1006-8.
  • Hansen V, Jakobsen B, Amesen E. Prevalence of serious psychiatric morbidity in attenders and nonattenders to a health survey of a general population: the Tromsø Health Study. Am J Epidemiol 2001;154:8914.
  • Bretteville-Jensen A, Oedegaard E. Injecting drug users in Norway. Report from the National Institute of Alcohol and Drug Research, Oslo 1999;4:82-3.
  • Hoel T, Skar A, Gutigard B, Skaug K. Hepatitis A-, B- and C-markers among intravenous drug abusers in Oslo [Abstract]. 9th International Congress on Infectious Diseases 2000, abstr. 22.022.
  • Ward C, Tudor-Williams G, Cotzias T, Hargreaves S, Regan L, Foster GR. Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing. Gut 2000;47:277-80.
  • Gangsoy-Kristiansen M, Berg L, Sjursen H, Mortensen L, Florholmen J. Hepatitis C in Northern Norway. Tidsskr Nor Lægeforn 2002;122:1974-6.
  • Tremolada F, Casarin C, Albeiti A, Drago C, Tagger A, Ribero ML, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-81.
  • Mattsson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 1993; 13:274-8.
  • Jamal MM, Soni A, Quinn PG, Wheeler DB, Arora S, Johnston DB. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the South-western United States. Hepatology 1999;30:1307-11.
  • Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001;34:1000-5.
  • Bell H, Helium K, Harthug S, Maeland A, Ritland S, Myrvang B, et al. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Scand J Infect Dis 1997;29:17-22.
  • Bjøro K, Bell H, Helium KB, Skaug K, Raknerud N, Sandvei P, et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002;37:226-32.
  • Bjøro K, Bell H, Helium KB, Skaug K, Raknerud N, Sandvei P, et al. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study. Scand J Gastroenterol 2002;37: 344-9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.